Phase II Study With Trastuzumab + Paclitaxel in Locally Advanced HER2+ Tumors or Epirubicin + Taxotere in HER2- Tumors
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
Prospective, monoinstitutional, phase II study. Patients with HER 2 positive locally advanced
breast cancer will be treated with 3 initial cycles (12 weeks) of trastuzumab plus paclitaxel
and then if responding further 12 weeks and then with surgical resection, patients with HER2
negative breast carcinoma will be treated with 4 cycles (12 weeks) of epirubicin and
taxotere. If responding 4 more cycles (12 weeks). Patients progressing will be treated
depending on physician's and patient's preference